Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

WuXi Biologics Announces $450 Million Bispecific Deal with Oxford BioTherapeutics

publication date: Dec 11, 2018

WuXi Biologics formed a $450 million partnership with England's Oxford BioTherapeutics to develop five novel bispecific antibodies, including a PD-L1 molecule, using its WuXiBody™ Platform. OBT says the bispecifics will combine two second-gen immunoncology targeting mechanisms in a single molecule to improve efficacy. Oxford will make an upfront payment plus milestones and royalties, though details were not disclosed. More details...

Stock Symbol: (HK: 2269)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.